10 March 2014 - Alexion Pharmaceuticals lifted its annual guidance after concluding discussions with the French government that will \"positively\" impact reimbursement for Soliris (eculizumab).

According to Alexion, the agreement with the French government provides reimbursement for shipments of Soliris made prior to January 1 this year. The drugmaker noted that the deal follows the French Transparency Commission designation with the ASMR 2 rating for Soliris in 2012 for the treatment of atypical haemolytic uraemic syndrome (aHUS) and paroxysmal nocturnal haemoglobinuria.

For more details, go to: http://news.alexionpharma.com/press-release/financial-news/alexion-revises-upward-2014-financial-gui...